Monday, 14 November 2022 8:30-18:00 (IN-PERSON ONLY)
Introduction to Bispecific Antibodies: History, Engineering, and Application
Introduction to Bispecific Antibodies will be organized as an informative and practical guide to get up to speed on critical aspects of bispecific antibody therapeutics. Topics will include historical successes, failures, and lessons learned. Specific
practical instruction will span mechanisms of action, engineering, developability, regulatory considerations, and translational guidelines. Perspectives on ideal implementation of bispecifics as targeted and immunomodulatory approaches will be discussed.
Topics to be Covered:
- A brief history of bispecific antibodies: 60 years of progress with critical advances and key pioneers
- Bispecific applications and powerful mechanisms of action
- Engineering bispecific antibodies: 100 formats and counting
- Bispecific-specific considerations in preclinical development and regulatory landscape
- Developability, manufacturing, and analytical considerations
- Clinical experience, translation, and regulatory approval
- Current trends and future opportunities in regulating immune checkpoints, cell-based therapies, and personalized approaches
G. Jonah Rainey, PhD, Vice President, Antibody Engineering, AlivaMab Discovery Services
Jonah Rainey holds a PhD in Biochemistry from Tufts University and completed postdoctoral training at the University of Wisconsin and the Salk Institute. He has engaged in discovery, research, and development of bispecific antibodies for more than 15
years. He is an inventor on several patents describing novel bispecific platforms and current clinical candidates that exploit these platforms. Jonah contributed to research and early development of multiple clinical candidates in phase 1 and 2, and
led many advanced preclinical programs in oncology, infectious disease, autoimmunity, and other therapeutic areas. Previous industry experience includes MacroGenics, MedImmune/AZ, Oriole Biotech and Gritstone Oncology.